RALOXIFENE vs RALOXIFENE HYDROCHLORIDE

Compare RALOXIFENE (Raloxifene Hydrochloride) and RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) — clinical data, side effects, and patient experiences.

RALOXIFENE

Raloxifene Hydrochloride, Evista · SERM

How it works

12.1 Mechanism of Action Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene ...

Approved for

1 INDICATIONS AND USAGE Raloxifene hydrochloride tablet

reduction of the risk of recurrence of breast cancer

or reduction of risk of noninvasive breast cancer. ( 1.3 ) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women Raloxifene hydrochloride tablets

USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1

OralTablet

RALOXIFENE HYDROCHLORIDE

Raloxifene Hydrochloride · SERM

How it works

12.1 Mechanism of Action Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene ...

Approved for

reduction of the risk of recurrence of breast cancer

one or more first-degree relatives with breast cancer

or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age

number of first-degree relatives with breast cancer

OralTablet

Quick Comparison

RALOXIFENERALOXIFENE HYDROCHLORIDE

Drug Class

SERM

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

RALOXIFENE

Nausea

1-10%

Falls

1-10%

Drug Not Working

1-10%

Limb Pain

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Fatigue

1-10%

Headache

1-10%

RALOXIFENE HYDROCHLORIDE

Nausea

1-10%

Falls

1-10%

Drug Not Working

1-10%

Limb Pain

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Fatigue

1-10%

Headache

1-10%

FDA Warnings

RALOXIFENE

5 WARNINGS AND PRECAUTIONS Venous Thromboembolism: Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
1 ) Death Due to Stroke: Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events
No increased risk of stroke was seen in this trial
Consider risk-benefit balance in women at risk for stroke

RALOXIFENE HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Venous Thromboembolism : Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
1) Death Due to Stroke : Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events
No increased risk of stroke was seen in this trial
Consider risk-benefit balance in women at risk for stroke

Clinical Trial Data

No head-to-head clinical studies found for RALOXIFENE vs RALOXIFENE HYDROCHLORIDE.

RALOXIFENE vs RALOXIFENE HYDROCHLORIDE: What You Should Know

Key Differences

Both RALOXIFENE and RALOXIFENE HYDROCHLORIDE belong to the SERM class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Shared Indications

Both medications are approved for reduction of the risk of recurrence of breast cancer, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

RALOXIFENE carries 4 FDA warnings. RALOXIFENE HYDROCHLORIDE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

RALOXIFENE HYDROCHLORIDE vs TAMOXIFEN CITRATE→RALOXIFENE HYDROCHLORIDE vs TOREMIFENE CITRATE→RALOXIFENE vs TAMOXIFEN CITRATE→RALOXIFENE vs TOREMIFENE CITRATE→RALOXIFENE vs TERIPARATIDE→RALOXIFENE vs ZOLEDRONIC ACID→

Loading comparison data...

RALOXIFENE vs RALOXIFENE HYDROCHLORIDE

Compare RALOXIFENE (Raloxifene Hydrochloride) and RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) — clinical data, side effects, and patient experiences.

RALOXIFENE

Raloxifene Hydrochloride, Evista · SERM

How it works

12.1 Mechanism of Action Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene ...

Approved for

1 INDICATIONS AND USAGE Raloxifene hydrochloride tablet

reduction of the risk of recurrence of breast cancer

or reduction of risk of noninvasive breast cancer. ( 1.3 ) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women Raloxifene hydrochloride tablets

USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1

OralTablet

RALOXIFENE HYDROCHLORIDE

Raloxifene Hydrochloride · SERM

How it works

12.1 Mechanism of Action Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene ...

Approved for

reduction of the risk of recurrence of breast cancer

one or more first-degree relatives with breast cancer

or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age

number of first-degree relatives with breast cancer

OralTablet

Quick Comparison

RALOXIFENERALOXIFENE HYDROCHLORIDE

Drug Class

SERM

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

RALOXIFENE

Nausea

1-10%

Falls

1-10%

Drug Not Working

1-10%

Limb Pain

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Fatigue

1-10%

Headache

1-10%

RALOXIFENE HYDROCHLORIDE

Nausea

1-10%

Falls

1-10%

Drug Not Working

1-10%

Limb Pain

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Fatigue

1-10%

Headache

1-10%

FDA Warnings

RALOXIFENE

5 WARNINGS AND PRECAUTIONS Venous Thromboembolism: Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
1 ) Death Due to Stroke: Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events
No increased risk of stroke was seen in this trial
Consider risk-benefit balance in women at risk for stroke

RALOXIFENE HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Venous Thromboembolism : Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
1) Death Due to Stroke : Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events
No increased risk of stroke was seen in this trial
Consider risk-benefit balance in women at risk for stroke

Clinical Trial Data

No head-to-head clinical studies found for RALOXIFENE vs RALOXIFENE HYDROCHLORIDE.

RALOXIFENE vs RALOXIFENE HYDROCHLORIDE: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.